Therefore, this review focuses on the indole and indole-based selective FLT3 inhibitors as promising scaffolds for developing more efficient FLT3 inhibitors, relying on the fact that FLT3 overexpression is involved in the aggressive and resistant AML pathophysiology. This evidence concerns the gene FLT3 and acute myeloid leukemia.